Revival

This title was first published in 2003: As new medical technologies and treatments develop with increasing momentum, the legal and ethical implications of research involving human participants are being called into question as never before.

George F. Tomossy works at Macquarie University, Australia, and David N. Weisstub works within the Faculté de médecine, Université de Montréal, Canada

Contents: Series preface; Introduction: human research ethics. Part I: The Historical and Philosophical Foundations: Philosophical reflections on experimenting with human subjects, Hans Jonas (1969); Experimenting on human subjects: philosophical perspectives, Ruth Macklin and Susan Sherwin (2004); Principlism and the ethical appraisal of clinical trials, Eric M. Meslin, Heather J. Sutherland, James V. Lavery and James E. Till; The Nuremberg code in light of previous principles and practices in human experimentation, David J. Rothman; Nuremberg's legacy: some ethical reflections, James F. Childress; The controversy over retrospective moral judgment, Allen Buchanan; Looking back and judging our predecessors, Tom L. Beauchamp; When evil intrudes, Arthur L. Caplan; Shading the truth in seeking informed consent for research purposes, Sissela Bok; Trust: the fragile foundation of contemporary biomedical research, Nancy E. Kass, Jeremy Sugarman, Ruth Faden and Monica Schoch-Spana; Questing for grails: duplicity, betrayal and self-deception in postmodern medical research, George J. Annas; Roles and fictions in clinical and research ethics, David N. Weisstub. Part II: Protecting Human Subjects: Human experimentation and human rights, Jay Katz; The social control of human biomedical research: an overview and review of the literature, Paul R. Benson; Goodbye to all that: the end of moderate protectionism in human subjects research, Jonathan D. Moreno; Is national, independent oversight needed for the protection of human subjects?, Alexander Morgan Capron; National, independent oversight: reinforcing the safety net for human subjects research, Anna C. Mastroianni; Regulating research for the decisionally impaired: implications for mental health professionals, Marshall B. Kapp; Are research ethics bad for our mental health?, Robert Michels; The reform of adult guardianship laws: the case of non-therapeutic experimentation; George F. Tomossy and David N. Weisstub. Part III: Risk and Responsibility: The ethical analysis of risk, Charles Weijer; Defining and describing benefit appropriately in clinical trials, Nancy M.P. King; What research with stored samples teaches us about research with human subjects, David Wendler; Uncertainty in clinical research; Robert J. Levine; Equipoise and the ethics of clinical research, Benjamin Freedman; Equipoise, knowledge and ethics in clinical research and practice, Richard Ashcroft; Ethical considerations concerning treatment allocation in drug development trials, S. Senn; When are placebo-controlled trials no longer appropriate?, Baruch A. Brody. Part IV: Globalization and Corporation - Trust and Participation: International research: ethical imperialism or ethical pluralism?, Ruth Macklin; Is academic medicine for sale?, Marcia Angell; Ethical issues in research relationships between universities and industry, James T. Rule and Adil E. Shamoo; Uneasy alliance - clinical investigators and the pharmaceutical industry, Thomas Bodenheimer; Ethics review for sale? Conflict of interest and commercial research review boards, Trudo Lemmens and Benjamin Freedman; Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach, Jesse A. Goldner; Restoring and preserving trust in biomedical research, Mark Yarborough and Richard R. Sharp; Privatized biomedical research, public fears, and the hazards of government regulation: lessons from stem cell research, David B. Resnik; Name index.